These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

243 related items for PubMed ID: 20137111

  • 1. [Correlation of adult AML Npm1 mutations with prognosis and its relationship with gene mutation of FLT3 and CEBPA].
    Bao LY, Wang JS.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Feb; 18(1):19-24. PubMed ID: 20137111
    [Abstract] [Full Text] [Related]

  • 2. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations.
    Green CL, Koo KK, Hills RK, Burnett AK, Linch DC, Gale RE.
    J Clin Oncol; 2010 Jun 01; 28(16):2739-47. PubMed ID: 20439648
    [Abstract] [Full Text] [Related]

  • 3. Transplant outcomes of the triple-negative NPM1/FLT3-ITD/CEBPA mutation subgroup are equivalent to those of the favourable ELN risk group, but significantly better than the intermediate-I risk group after allogeneic transplant in normal-karyotype AML.
    Ahn JS, Kim HJ, Kim YK, Jung SH, Yang DH, Lee JJ, Kim NY, Choi SH, Jung CW, Jang JH, Kim HJ, Moon JH, Sohn SK, Won JH, Kim SH, Kim DD.
    Ann Hematol; 2016 Mar 01; 95(4):625-35. PubMed ID: 26692090
    [Abstract] [Full Text] [Related]

  • 4. Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia.
    Shamaa S, Laimon N, Aladle DA, Azmy E, Elghannam DM, Salem DA, Taalab MM.
    Hematology; 2014 Jan 01; 19(1):22-30. PubMed ID: 23540998
    [Abstract] [Full Text] [Related]

  • 5. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
    Zheng WS, Hu YL, Guan LX, Peng B, Wang SY.
    Hematology; 2021 Dec 01; 26(1):179-185. PubMed ID: 33594943
    [Abstract] [Full Text] [Related]

  • 6. [NPM1 and CEBPA mutations in pediatric cytogenetically normal acute myeloid leukemia].
    Ruan M, Zhang L, Han C, Liu X, Ai X, Zhang J, Liu T, Yang W, Chen X, Guo Y, Wang S, Li Q, Zou Y, Chen Y, Zhu X.
    Zhonghua Er Ke Za Zhi; 2014 Apr 01; 52(4):303-7. PubMed ID: 24915920
    [Abstract] [Full Text] [Related]

  • 7. NPM1, FLT3 and CEBPA mutations in pediatric patients with AML from Argentina: incidence and prognostic value.
    Rubio P, Campos B, Digiorge JA, Gallego MS, Medina A, Rossi JG, Felice MS, Alonso CN.
    Int J Hematol; 2016 Nov 01; 104(5):582-590. PubMed ID: 27436336
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Clinical significance of FLT3-ITD/CEBPA mutations and minimal residual disease in cytogenetically normal acute myeloid leukemia after hematopoietic stem cell transplantation.
    Wang H, Li XQ, Chu TT, Han SY, Qi JQ, Tang YQ, Qiu HY, Fu CC, Tang XW, Ruan CG, Wu DP, Han Y.
    J Cancer Res Clin Oncol; 2021 Sep 01; 147(9):2659-2670. PubMed ID: 33550446
    [Abstract] [Full Text] [Related]

  • 10. CEBPA single mutation can be a possible favorable prognostic indicator in NPM1 and FLT3-ITD wild-type acute myeloid leukemia patients with intermediate cytogenetic risk.
    Park SH, Chi HS, Cho YU, Jang S, Park CJ.
    Leuk Res; 2013 Nov 01; 37(11):1488-94. PubMed ID: 24054719
    [Abstract] [Full Text] [Related]

  • 11. [Clinical characteristics of newly diagnosed acute myeloid leukemia patients with NPM1 mutation].
    Wei H, Zhang YQ, Lin D, Wang Y, Zhou CL, Liu BC, Li W, Rao Q, Wang M, Mi YC, Wang JX.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Feb 01; 22(1):11-5. PubMed ID: 24598642
    [Abstract] [Full Text] [Related]

  • 12. [Detection of NPM1, FLT3 and C-KIT mutations in acute myeloid leukemia and their prognostic analysis].
    Li L, Lyu XD, Mi RH, Ding J, Chen L, Wang Q, Yin QS, Hu JY, Fan RH, Wei XD.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun 01; 21(3):601-6. PubMed ID: 23815906
    [Abstract] [Full Text] [Related]

  • 13. FLT3 and NPM1 mutations in a cohort of AML patients and detection of a novel mutation in tyrosine kinase domain of FLT3 gene from Western India.
    Ghosh K, Swaminathan S, Madkaikar M, Gupta M, Kerketta L, Vundinti B.
    Ann Hematol; 2012 Nov 01; 91(11):1703-12. PubMed ID: 22733614
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [A study of NPM1 and FLT3 gene mutations in acute myeloid leukemia].
    Wu DP, Yan LZ, Yang L, Chen SN, Wu XJ, Liang JY.
    Zhonghua Nei Ke Za Zhi; 2007 Nov 01; 46(11):907-10. PubMed ID: 18261272
    [Abstract] [Full Text] [Related]

  • 16. Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 years: a systematic review and meta-analysis.
    Port M, Böttcher M, Thol F, Ganser A, Schlenk R, Wasem J, Neumann A, Pouryamout L.
    Ann Hematol; 2014 Aug 01; 93(8):1279-86. PubMed ID: 24801015
    [Abstract] [Full Text] [Related]

  • 17. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.
    Schlenk RF, Döhner K, Krauter J, Fröhling S, Corbacioglu A, Bullinger L, Habdank M, Späth D, Morgan M, Benner A, Schlegelberger B, Heil G, Ganser A, Döhner H, German-Austrian Acute Myeloid Leukemia Study Group.
    N Engl J Med; 2008 May 01; 358(18):1909-18. PubMed ID: 18450602
    [Abstract] [Full Text] [Related]

  • 18. The prognostic impact of FLT3-ITD, NPM1 and CEBPa in cytogenetically intermediate-risk AML after first relapse.
    Kurosawa S, Yamaguchi H, Yamaguchi T, Fukunaga K, Yui S, Kanamori H, Usuki K, Uoshima N, Yanada M, Takeuchi J, Mizuno I, Kanda J, Okamura H, Yano S, Tashiro H, Shindo T, Chiba S, Tomiyama J, Inokuchi K, Fukuda T.
    Int J Hematol; 2020 Aug 01; 112(2):200-209. PubMed ID: 32495317
    [Abstract] [Full Text] [Related]

  • 19. CD34 expression predicts an adverse outcome in patients with NPM1-positive acute myeloid leukemia.
    Dang H, Chen Y, Kamel-Reid S, Brandwein J, Chang H.
    Hum Pathol; 2013 Oct 01; 44(10):2038-46. PubMed ID: 23701943
    [Abstract] [Full Text] [Related]

  • 20. C/EBPA gene mutation and C/EBPA promoter hypermethylation in acute myeloid leukemia with normal cytogenetics.
    Lu Y, Chen W, Chen W, Stein A, Weiss LM, Huang Q.
    Am J Hematol; 2010 Jun 01; 85(6):426-30. PubMed ID: 20513120
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.